



Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

Michelino De Laurentiis¹ · Simona Borstnar² · Mario Campone³ · Ellen Warner⁴ · Javier Salvador Bofill⁵ · William Jacot⁶ · Susan Dent^{7,17} · Miguel Martin⁸ · Alistair Ring⁹ · Paul Cottu¹⁰ · Janice Lu¹¹ · Eva Ciruelos¹² · Hamdy A. Azim¹³ · Sanjoy Chatterjee¹⁴ · Katie Zhou¹⁵ · Jiwen Wu¹⁵ · Lakshmi Menon-Singh¹⁵ · Claudio Zamagni¹⁶

Published online: 8 October 2021
© The Author(s) 2021

Correction to: Breast Cancer Research and Treatment
<https://doi.org/10.1007/s10549-021-06334-0>

The article “Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population”, written by Michelino De Laurentiis, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, William Jacot, Susan Dent, Miguel Martin, Alistair Ring, Paul Cottu, Janice Lu, Eva Ciruelos, Hamdy A. Azim, Sanjoy Chatterjee, Katie Zhou, Jiwen Wu, Lakshmi Menon-Singh and Claudio Zamagni, was originally published electronically on the publisher’s internet portal on 19 August 2021 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article

changed on 27 August 2021 to © The Author(s) 2021 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To

The original article can be found online at <https://doi.org/10.1007/s10549-021-06334-0>.

✉ Michelino De Laurentiis
m.delautentiis@istitutotumori.na.it

¹ Division of Breast Medical Oncology, Department of Breast and Thoracic Oncology Director, Istituto Nazionale Tumori IRCCS “Fondazione Pascale”, Napoli, Italy

² Institute of Oncology Ljubljana, Ljubljana, Slovenia

³ Western Cancer Institute, Nantes, France

⁴ Sunnybrook Health Sciences Centre, Toronto, ON, Canada

⁵ Virgen del Rocío University Hospital, Biomedicine Institute, Seville, Spain

⁶ Montpellier Cancer Institute, Montpellier, France

⁷ The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

⁸ Gregorio Marañón General University Hospital, GEICAM, Universidad Complutense, CIBERONC, Madrid, Spain

⁹ Royal Marsden Hospital NHS Foundation Trust, Sutton, UK

¹⁰ Curie Institute, Paris, France

¹¹ USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

¹² University Hospital 12 de Octubre, Clara Campal Comprehensive Cancer Center (HM CIOCC), Madrid, Spain

¹³ Faculty of Medicine, Cairo University, Cairo, Egypt

¹⁴ Tata Medical Center, Kolkata, India

¹⁵ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

¹⁶ Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italia

¹⁷ Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA

view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0>.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated

otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.